Tomoya Shimokata
Overview
Explore the profile of Tomoya Shimokata including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Takano Y, Shimokata T, Urakawa H, Kikumori T, Ando Y
Int Cancer Conf J
. 2024 Jul;
13(3):184-188.
PMID: 38962055
Solid tumors harboring mutations in the Braf gene () are currently treated by combination Braf/MEK inhibitor therapy, and there is an extensive literature on patient response rates. Alternatively, few studies...
2.
Kobayashi T, Iwama S, Yamagami A, Izuchi T, Suzuki K, Otake K, et al.
Cancer Immunol Immunother
. 2024 Jun;
73(8):146.
PMID: 38833157
Background: Anti-programmed cell death-1 (ligand-1) antibody [PD-(L)1-Ab] can cause destructive thyroiditis and/or hypothyroidism. In addition, tyrosine kinase inhibitors (TKIs) frequently induce hypothyroidism. The aim of this prospective study is to...
3.
Ito T, Mizuno K, Yamamoto T, Yasuda T, Yokoyama S, Yamamoto K, et al.
Hepatol Res
. 2024 Apr;
54(11):1060-1069.
PMID: 38571477
Aim: To detect immune-related adverse events (irAEs) early and treat them appropriately, our institute established an irAE-focused multidisciplinary toxicity team in cooperation with various departments. This study aimed to evaluate...
4.
Ushijima F, Hase T, Yamashita Y, Kim H, Shimokata T, Kondo C, et al.
Int Cancer Conf J
. 2024 Mar;
13(2):88-92.
PMID: 38524642
Little is known about the efficacy and safety of durvalumab plus carboplatin-etoposide treatment in patients with extensive-disease (ED) small-cell lung cancer (SCLC) on hemodialysis. Here, we present a case of...
5.
Liang Y, Maeda O, Shimokata T, Yokota K, Koike H, Sakai T, et al.
Int Cancer Conf J
. 2024 Jan;
13(1):63-67.
PMID: 38187185
Supplementary Information: The online version contains supplementary material available at 10.1007/s13691-023-00638-2.
6.
Hatta T, Hase T, Hara T, Kimura T, Kojima E, Abe T, et al.
Cancer Med
. 2023 Jun;
12(15):15955-15969.
PMID: 37351560
Background: The Cockcroft-Gault formula is commonly used as a substitute for glomerular filtration rate (GFR) in Calvert's formula for carboplatin dosing, where adjusting serum creatinine measured using the enzymatic method...
7.
Ando Y, Morita S, Shimokata T, Tsuzuki T, Inafuku S, Iwami K, et al.
Int Cancer Conf J
. 2022 Oct;
11(4):242-246.
PMID: 36186229
For decades, no clear consensus existed on the standard treatment option for malignant tumors of the external auditory canal, an extremely rare disease. Here we report the case of a...
8.
Mitsuma A, Ito Y, Shimokata T, Tanaka C, Uehara K, Nakayama G, et al.
Cancer Diagn Progn
. 2022 May;
2(3):330-335.
PMID: 35530649
Background/aim: Antiangiogenic chemotherapy is the backbone of the various anticancer therapies. To date no practical biomarker predicting their antitumor effects and toxicity has been reported. We aimed to determine the...
9.
Furune S, Kondo C, Takano Y, Shimokata T, Sugishita M, Mitsuma A, et al.
Int Cancer Conf J
. 2022 Feb;
11(1):49.
PMID: 35129544
[This corrects the article DOI: 10.1007/s13691-021-00515-w.].
10.
Takano Y, Furune S, Miyai Y, Morita S, Inoue M, Shimokata T, et al.
Int Cancer Conf J
. 2022 Feb;
11(1):67-70.
PMID: 35116219
Here, we report a 57-year-old female patient with HER2-positive recurrent gastric cancer who experienced drug-induced thrombocytopenia associated with trastuzumab, a humanized anti-HER2 monoclonal antibody. Shortly after the initiation of S-1,...